Scholarlink

Introduction <p>The efficacy of erythropoiesis-stimulating agents (ESAs) for transfusion-dependent (TD) anemia in lower-risk myelodysplastic syndromes (LR-MDS) is limited. Luspatercept achieved significantly greater rates of red blood cell (RBC) transfusion independence (TI) versus epoetin alfa (an ESA) in the phase 3 COMMANDS trial. This analysis assessed long-term RBC-TI, cumulative response, and safety with luspatercept in COMMANDS.</p> Methods <p>Eligible patients aged ≥&#xa0;18&#xa0;years, with ESA-naive, RBC TD LR-MDS were randomized 1:1 to receive luspatercept (1.0&#xa0;mg/kg, titration to 1.75&#xa0;mg/kg permitted) or epoetin alfa (450&#xa0;IU/kg, titration to 1050&#xa0;IU/kg). Disease assessment was carried out at week&#xa0;24 (day&#xa0;169) and every 24&#xa0;weeks thereafter. Treatment continued until disease progression, lack of clinical benefit, unacceptable toxicity, or consent withdrawal.</p> Results <p>At data cutoff (September 22, 2023; median follow-up: luspatercept 21.4&#xa0;months, epoetin alfa 20.3&#xa0;months), a greater proportion of patients treated with luspatercept (<i>n</i>&#xa0;=&#xa0;182) versus epoetin alfa (<i>n</i>&#xa0;=&#xa0;181) achieved a longest single RBC-TI period ≥&#xa0;1&#xa0;year (44.5% vs. 27.6%; <i>P</i>&#xa0;=&#xa0;0.0003) and ≥&#xa0;1.5&#xa0;years (30.2% vs. 13.8%; <i>P</i>&#xa0;&lt;&#xa0;0.0001). Higher rates of RBC-TI ≥&#xa0;1.5&#xa0;years with luspatercept over epoetin alfa were consistent across all prespecified subgroups, including patients with ring sideroblast-negative status and low baseline serum erythropoietin. Longer cumulative RBC-TI response [sum of all durations of RBC-TI for ≥&#xa0;12&#xa0;weeks; week&#xa0;1 to end of treatment (95% CI)] was observed with luspatercept [154.7&#xa0;weeks (118.4–NR)] versus epoetin alfa [91.1&#xa0;weeks (73.1–123.9)]. Rates of treatment-emergent adverse events, including asthenia and hypertension, generally decreased over time in both arms. Progression rates to high-risk MDS and acute myeloid leukemia were similarly low (&lt;&#xa0;5%) in both treatment arms.</p> Conclusions <p>These data demonstrated sustained, durable clinical benefit across subgroups and support luspatercept as the treatment of choice for anemia in patients with LR-MDS who are TD and ESA-naive.</p> Trial Registration Number <p>NCT03682536.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月16日

查看全文
  • Guillermo Garcia-Manero,
  • Valeria Santini,
  • Amer M. Zeidan,
  • Rami S. Komrokji,
  • Veronika Pozharskaya,
  • Shelonitda Rose,
  • Karen Keeperman,
  • Yinzhi Lai,
  • Sameer Kalsekar,
  • Barkha Aggarwal,
  • Dimana Miteva,
  • David Valcárcel,
  • Pierre Fenaux,
  • Jake Shortt,
  • Matteo Giovanni Della Porta,
  • Uwe Platzbecker

摘要

Introduction

The efficacy of erythropoiesis-stimulating agents (ESAs) for transfusion-dependent (TD) anemia in lower-risk myelodysplastic syndromes (LR-MDS) is limited. Luspatercept achieved significantly greater rates of red blood cell (RBC) transfusion independence (TI) versus epoetin alfa (an ESA) in the phase 3 COMMANDS trial. This analysis assessed long-term RBC-TI, cumulative response, and safety with luspatercept in COMMANDS.

Methods

Eligible patients aged ≥ 18 years, with ESA-naive, RBC TD LR-MDS were randomized 1:1 to receive luspatercept (1.0 mg/kg, titration to 1.75 mg/kg permitted) or epoetin alfa (450 IU/kg, titration to 1050 IU/kg). Disease assessment was carried out at week 24 (day 169) and every 24 weeks thereafter. Treatment continued until disease progression, lack of clinical benefit, unacceptable toxicity, or consent withdrawal.

Results

At data cutoff (September 22, 2023; median follow-up: luspatercept 21.4 months, epoetin alfa 20.3 months), a greater proportion of patients treated with luspatercept (n = 182) versus epoetin alfa (n = 181) achieved a longest single RBC-TI period ≥ 1 year (44.5% vs. 27.6%; P = 0.0003) and ≥ 1.5 years (30.2% vs. 13.8%; P < 0.0001). Higher rates of RBC-TI ≥ 1.5 years with luspatercept over epoetin alfa were consistent across all prespecified subgroups, including patients with ring sideroblast-negative status and low baseline serum erythropoietin. Longer cumulative RBC-TI response [sum of all durations of RBC-TI for ≥ 12 weeks; week 1 to end of treatment (95% CI)] was observed with luspatercept [154.7 weeks (118.4–NR)] versus epoetin alfa [91.1 weeks (73.1–123.9)]. Rates of treatment-emergent adverse events, including asthenia and hypertension, generally decreased over time in both arms. Progression rates to high-risk MDS and acute myeloid leukemia were similarly low (< 5%) in both treatment arms.

Conclusions

These data demonstrated sustained, durable clinical benefit across subgroups and support luspatercept as the treatment of choice for anemia in patients with LR-MDS who are TD and ESA-naive.

Trial Registration Number

NCT03682536.